Published: 2 May 2022
Author(s): Zhitong Li, Quanbo Liu, Fei Liu, Tesfaldet H. Hidru, Yiheng Yang, Shihao Wang, Lan Bai, Jing Chen, Xiaolei Yang, Yunlong Xia
Issue: June 2022

Acute myocardial infarction (AMI) remains one of the leading causes of mortality globally, new-onset AF (NOAF) after AMI is a common complication of AMI, with an incidence of 6% to 21% [1], which is a well-established factor of worse short- and long-term prognosis [2,3]. However, the development of AF is multifactorial and the mechanisms are not well-understood [4,5]. Therefore, early identification of high-NOAF-risk patients is still of great clinical value.

Newsletters

Stay informed on our latest news!